Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -1.32% 7.45 61,393 09:30:26
Bid Price Offer Price High Price Low Price Open Price
7.30 7.60 7.55 7.45 7.55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.12 -2.74 10
Last Trade Time Trade Type Trade Size Trade Price Currency
16:23:55 O 19,920 7.50 GBX

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma (EVG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

DateSubject
08/12/2019
08:20
Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 7.55p.
Evgen Pharma Plc has a 4 week average price of 5.50p and a 12 week average price of 5.50p.
The 1 year high share price is 28.50p while the 1 year low share price is currently 5.50p.
There are currently 132,646,263 shares in issue and the average daily traded volume is 22,686 shares. The market capitalisation of Evgen Pharma Plc is £9,882,146.59.
12/11/2019
15:06
asat91: It is an interesting opportunity this because it's a pharma with an asset that has positive data in one indication at phase II, and non-significant (negative data) in another indication at phase II. Does the negative data for SAS indication warrant a share price drop of 60%, and a market cap of 10 million? Is 10 million fair value for what the company has at the moment? That's the golden question. Maybe the answer is yes, maybe it is no. What do you think?
13/10/2019
12:18
pennyfalls: Problem is, the trading cycle becomes a self-fulfilling prophecy. Each item of good news (and there’s been many) brings an attendant spike, then slowly but surely back to the support levels circa 13.5p-15p (and maybe even testing an all-time low one this time), plus fundraiser. So investors see the well-defined pattern and act accordingly. However at some point there will be (should be) an inflection point where traction holds with the share price. This could be positive SAH + forward funding/licensing then Autism trials etc (coming in quick succession), or it could be further down the line at SAH phaseIII or next STEM trials. But all depends on the next RNS being a good one, so I’ll take it from there and see what comes
11/10/2019
19:05
90005nelson: The Directors have good skin in the game here. There's also two chances of success with SFX-01 from STEM & SAH. EVG has stated that potential partners need to pay an upfront payment of $50M & &70M. Companies house has been fully updated. The removal of pre-emption rights. There's movement behind the scenes as we wait for the SAH results. Orphan drug status is obtained as with virtually all the worldwide patents. I don't expect the share price to be at this level within next few months.
11/10/2019
18:40
pennyfalls: All posts look quite positive to me Dave, with some good knowledge. Outcome wont be linked to ADVFN posts, and neither will Share price.
10/10/2019
14:05
90005nelson: I agree with your timeline for the news. LTH are also derisking as they watch previous profits evaporate.The share price is now below my average and represents 13.3% of my portfolio. I'm happy to divert other profits, as & when, into the lower price.
26/9/2019
11:29
timbo003: A few thoughts following some of the recent comments on the SAH study First of all, it is worth bearing in mind the market’s perceived potential value (and risk adjusted value) of the company’s clinical assets: Finncap Initiation note (April 2019) Metastatic breast cancer value of (£30m) 30p per share that would rise to c.£60m (60p) on a successful Phase IIb study. This excludes any upfront licensing payment that would be expected on successful completion of the proposed Phase IIb study. This could be of the order of order of $50m or c.35-40p per share. The de-risked NPV is c.£300m (excluding upfronts and/or milestones). Subarachnoid haemorrhage value of £14m (15p per share). A positive readout of its Phase IIb study in Q3 2019 would value the potential royalty stream at c.£50m, which together with the value of a potential upfront payment (c.£30m), should the company license the asset, implies an asset value of c.£80m. Our target price attributes no value to any investigator-initiated studies in which Evgen would supply SFX-01 for Phase II trials in fatty liver disease (NASH), autism spectrum disorder and intra-cerebral haemorrhage (ICH) whilst retaining all commercial rights. Our target price valuation would rise to at least c.£80m (80p) on a successful Phase IIb trial result in SAH. The downside risk, should the trial fail, is around 7p in our opinion. The current share price is more than supported by the breast cancer indication alone (c.30p). Finncap update (May 2019) The Phase IIb trial of SFX-01 in subarachnoid haemorrhage (SAH) is expected to readout in Q3 2019, following advice from clinicians and statisticians to leave the study blinded until completion of both primary and secondary cognitive endpoints at six months post treatment. A successful outcome would see our risk-adjusted value for this indication rise from c.£15m to c.£80m. Our forecasts are unchanged apart from cash and LPS, which is reduced to take account of the 25% enlargement of share capital. Our target price is reduced to 35p to reflect this dilution. Our risk-adjusted target valuation of c.£45m would rise to c.£110m upon a successful Phase IIb readout for SAH, implying an increase in the target price to c.85p. On March 18th the company stated: Following advice from clinicians and statisticians, and in the light of commercial considerations, the Company has decided to announce the primary endpoints (safety, tolerability and measures of blood flow in the brain) and secondary endpoints (relating to cognitive function) at the same time, rather than announcing them separately as previously indicated. I would have been very surprised if they hadn’t taken that decision given the study design. The primary outcome is cerebral blood flow and one of the the secondary outcomes is cognitive function ( 7 , 28, 90 and 180 days post stroke). In reality, everyone (i.e. Clinicians, Investors and potential partners) will be far more focused on the secondary than the primary, so why compromise the blinding (and the statistical significance) for the outcome which is of most interest by prematurely analysing and reporting result from the primary measure (which will be of much less interest)? This is particularly relevant in the SAH study as the cognitive function will be assessed using the modified Rankin scale (0-6 ordinal scale) https://clinicaltrials.gov/ct2/show/NCT02614742?term=evgen&rank=2 This will inevitably involve some subjectivity when assigning a score (with the obvious exception of scoring a maximum 6), therefore it extremely important to maintain the integrity of the blinding https://en.wikipedia.org/wiki/Modified_Rankin_Scale http://www.modifiedrankin.com/input? Given the lack lustre share price action in the last few weeks, investors are bound to ask themselves, does someone already know the outcome of the study? I think the answer to that is almost certainly no, with the small caveat that in some blinded studies where the design is control vs active, it is sometimes possible for the investigator to make an educated guess as to whether the active is having any effect, for example when one of the outcomes is unavoidably obvious (for example mortality rate). For SAH on average around 40% of patients on standard of care die within 30 days and for the survivors c.50% will have long-term cognitive impairment, so if the investigator sees no perceptible improvement for these measures when looking at the combined blinded placebo and active treatments, they may come to the conclusion that the active treatment is probably ineffective, on the other hand if they see the mortality rate at 30% or lower and improved (lower) Rankin scores, they may conclude that the active is probably having an effect.
24/9/2019
09:09
asat91: Well I was about to share similar concerns so don't regret sharing too much. The overly positive tone of the most recent RNS releases about breast cancer results are what indicate to me that they are worried about the SAH results and trying to avoid a significant share price drop. I mean why are they even releasing an RNS on the breast cancer results! The results came out a while back, and there's nothing new in these releases that requires sharing with shareholders. So why upload it at all? The timing seems very coincidental 1/2 months before SAH results.
23/9/2019
12:46
lovewinshatelosses: So, another positive RNS and yet no great movement in the share price today so far. Do people think that this is because the statistical significance is yet to be proven on a large enough scale and/or for a long enough time period, or is it something else? Regardless, I too would like to add my best wishes to blakeysangel, whose positivity I really respect and whose updates I appreciate.
29/7/2019
11:42
pdt: hsm12 - as you say any hint of efficacy and the share price could multiply. What I think is interesting is that any hint of efficacy could be a read across to Stroke in general where the market opportunity is x20 that of SAH. Although in SAH you are trying to mitigate a delayed ischemia there seems some evidence that sfx-01 could assist recovery post the initial event. This is what they said in the Interims in December 2018; "In our collaboration with Professor Giovanni E. Mann at King's BHF Centre of Research Excellence, King's College London, we have also been investigating the effects of SFX-01 in an in-vivo model of ischaemic stroke. The studies include Laser Speckle Blood Flow Imaging, a technology that shows real-time blood flow around the brain, before, during and after an experimental stroke. Whilst still ongoing, the study has shown that preconditioning with SFX-01 (i.e. three days dosing prior to stroke) improves the blood flow to the site of the stroke and this results in improved measures of functional and motor deficit. Notably, both pre-treatment and acute treatment with SFX-01 after ischaemic stroke rescued blood flow on reperfusion, suggesting that SFX-01 is protective if given before a stroke. This is promising with regard to our SAS clinical trial, where SFX-01 is administered days in advance of the ischaemia that follows the initial haemorrhage." Certainly interesting times for Evgen.
13/6/2018
11:14
teddy boy1: There should be a law against what has happened this morning ;the way the share price was systematically taken down to encourage more sales.This share is definitely being "worked " and the bottom line is that all the shorters and the market makers have made themselves a shed load of money over the past 3 days- and this is on a GOOD trial update ! Think of what would have happened if the news had been bad! On second thoughts the share price would not have been too much different ,left to its own devices. Anyhow this is AIM , and this is how things are ! Perhaps companys such as EVGEN and IDP with very tightly held shares should be avoided like the plague as they are prime candidates for manipulation . With such companys;until they have proved themselves 100 per cent, the seeds of doubt will be sown and before we know where we are the share price has been worked down until the share price bears no resemblance to its true value. This is a real pity as I have not read anything myself which would encourage me to dispose of my shares as, as far as I am concerned ,Evgen Pharma has a very bright future .However ,it could still be many months/years before we are allowed a TRUE share price which values the company for what it is worth and not what some individuals CAUSE it to be, in the quest to make some easy money for themselves, over and over again! Anyone else agree with my sentiments?
Evgen Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191209 05:53:04